Sunshine Biopharma fell 82.9% from $14.10 to $2.41, behind the S&P 500's +10.2%. Its worst day was May 15 (−39.5%), and its low came Oct 22 at $0.17.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Sunshine Biopharma closed at its highest level of the year, 5.0% above where the year started.
+5.7%
EPS of $-92.00 missed the $-54.00 estimate on $8.6M revenue (est. $10.0M).
+9.4% · S&P 500 +0.5%
EPS of $-50.00 missed the $-32.00 estimate on $8.1M revenue (est. $9.2M).
−28.9% · S&P 500 +0.8%
EPS of $-23.00 beat the $-24.00 estimate on $9.3M revenue (est. $8.6M).
−2.6% · S&P 500 −0.5%
Sunshine Biopharma closed at its lowest level of the year, 98.8% below where the year started.
−22.5% · S&P 500 −1.2%
EPS of $-5.20 missed the $-3.40 estimate on $9.4M revenue (est. $9.6M).
−4.9% · S&P 500 −0.4%
Where it ended: a close of $2.41 on Nov 18, 2026.
Nothing in the past 12 months.
All SBFM analyst actionsNothing in the past 12 months.
All SBFM dividend history